|
0
|
|
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
(linkinghub.elsevier.com)
|
Davies MJ
…
Sjostrom CD
The Lancet
2026-06-20
|
#clinical trial
#metabolic syndrome
#pharmacotherapy
#obesity
#glp-1
|
|
0
|
|
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.
(linkinghub.elsevier.com)
|
Shen L
…
Ji J
The Lancet
2026-06-20
|
#cancer
#clinical trial
#immunotherapy
#chemotherapy
#gastric
|
|
0
|
|
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
(linkinghub.elsevier.com)
|
Aroda VR
…
Rosenstock J
The Lancet
2026-06-20
|
#metabolism
#clinical trial
#diabetes
#drug development
|
|
0
|
|
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
(linkinghub.elsevier.com)
|
Lenz G
…
Vitolo U
The Lancet
2026-06-20
|
#antibody
#clinical trial
#immunotherapy
#chemotherapy
#lymphoma
|